Biogen announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s commitment to making responsible business decisions in the best interests of all its stakeholders. “As we reflect on the past year and set our sights on the path ahead, I am truly inspired by the progress we have made to advance Biogen’s enduring legacy of pioneering innovative science to deliver medicines that transform patients’ lives and create value for our communities and our shareholders,” said Christopher A. Viehbacher, Biogen President and Chief Executive Officer. “Our mission and business strategy are grounded in our commitment to responsible business, and in 2023, we refined our corporate responsibility strategy to advance our evolving business priorities and align with areas where we believe we can have the greatest impact.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen Reports Progress on Corporate Responsibility Priorities
- Sage Therapeutics price target lowered to $15 from $26 at RBC Capital
- Biogen announces CHMP opinion recommending Tofidence
- Biogen receives positive CHMP opinion for TOFIDENCE
- Sage Therapeutics price target lowered to $18 from $22 at Truist